|

Treatment arm: TSL2109 capsules。Oral administration。 Clinical Trials

1 actively recruiting trial

Also known as: DYRK2-CDK4/6

Pipeline

Phase 1: 1

Top Sponsors

  • Tasly Pharmaceutical Group Co., Ltd1

Indications

  • Metastatic Castration-Resistant Prostate Cancer Patients1
  • Cancer1

Other1 trial

TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.